In it's current formulation, i don't believe it looks promising as a treatment for full blown sepsis/bacteraemia, and I get that impression from this presentation also.
Looking great as a UTI/pre-sepsis treatment, which is still a massive market. And possibly some sort of formulation change such as protein binding could improve the plasma concentration profile.
Still hugely undervalued, but wish management would be more up front.
Ann: Investor Presentation - Spark Plus Healthcare Day, page-3
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
51.5¢ |
Change
-0.020(3.74%) |
Mkt cap ! $119.4M | |||
| Open | High | Low | Value | Volume |
| 54.0¢ | 54.0¢ | 51.0¢ | $22.11K | 42.39K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 25000 | 52.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 54.0¢ | 50541 | 5 |
View Market Depth
| Last trade - 15.48pm 03/10/2024 (20 minute delay) ? |
| RCE (ASX) Chart |